Protocol Number; CAIN457L1401

A special drug use-results survey to evaluate the safety and efficacy of subcutaneous administration of Cosentyx in pediatric patients with psoriasis vulgaris, psoriatic arthritis, or pustular psoriasis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031210589

Enrollment

Registered

2022-01-31

Start date

2022-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis vulgaris,psoriatic arthritis,pustular psoriasis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who have obtained written consent from their legally acceptable representative to cooperate in this survey before the start of treatment with this drug 2.Patients aged less than 18 years at the start of treatment with this drug 3.Patients newly treated with this drug for any of the following diseases: Psoriasis vulgaris, psoriatic arthritis, pustular psoriasis

Exclusion criteria

Exclusion criteria: 1.Prior treatment with this drug 2.Participation in an interventional study (e.g., a clinical trial) at the time of starting this drug.

Design outcomes

Primary

Measure	Time frame
Incidence of serious adverse events(52weeks)	—

Contacts

Public ContactNovartis Direct

Novartis Pharma. K.K.

sm.pms@novartis.com+81-120003293

Outcome results